Clinical aspects of mCRPC management in patients treated with radium-223
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical aspects of mCRPC management in patients treated with radium-223
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-21
DOI
10.1038/s41598-020-63302-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization
- (2019) Minh-Phuong Huynh-Le et al. Clinical Genitourinary Cancer
- Current perspectives on bone metastases in castrate-resistant prostate cancer
- (2018) Christopher Logothetis et al. CANCER AND METASTASIS REVIEWS
- eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
- (2018) Neal D. Shore et al. Clinical Genitourinary Cancer
- Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort
- (2018) John Tyler Rathbun et al. CURRENT PROBLEMS IN CANCER
- Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
- (2018) Christopher C. Parker et al. EUROPEAN UROLOGY
- 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience
- (2018) Giuseppe Boni et al. TUMORI
- 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience
- (2018) Giuseppe Boni et al. TUMORI JOURNAL
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer
- (2018) Joe M. O'Sullivan et al. EUROPEAN UROLOGY
- Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
- (2017) Tai-Lung Cha et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
- (2017) Oliver Sartor et al. ONCOLOGIST
- The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience
- (2017) Rossella De Luca et al. ONCOLOGY
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Radium 223 dichloride for prostate cancer treatment
- (2017) Emmanuel Deshayes et al. Drug Design Development and Therapy
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
- (2016) Fred Saad et al. LANCET ONCOLOGY
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- (2015) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone
- (2014) P. D. Ottewell et al. ENDOCRINE-RELATED CANCER
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia
- (2013) H. Ludwig et al. ANNALS OF ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer
- (2013) C. J. Logothetis et al. Cancer Discovery
- Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron
- (2012) M. Aapro et al. ANNALS OF ONCOLOGY
- Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
- (2012) Colleen M. Costelloe et al. Journal of Cancer
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started